Regular Article CLINICAL TRIALS AND OBSERVATIONS Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
نویسندگان
چکیده
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia Sarah Bertoli, Emilie Bérard, Françoise Huguet, Anne Huynh, Suzanne Tavitian, François Vergez, Sophie Dobbelstein, Nicole Dastugue, Véronique Mansat-De Mas, Eric Delabesse, Eliane Duchayne, Cécile Demur, Audrey Sarry, Valérie Lauwers-Cances, Guy Laurent, Michel Attal, and Christian Récher
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are associated with adverse prognosis. The important role played by FLT3 in the survival and proliferation of blasts, and its overexpression in most patients with AML, make FLT3 an attractive therapeutic target. We undertook a phase 2 trial of the FL...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children’s Cancer Group
Intensive, myelosuppressive therapy is necessary to maximize outcomes for patients with acute myeloid leukemia (AML). A comparison was made of 3 aggressive postremission approaches for children and adolescents with AML in a randomized trial, CCG2891.Atotal of 652 children and adolescents with AML who achieved remission on 2 induction regimens using identical drugs and doses (standard and intens...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
The median age at the time of diagnosis of acute myeloid leukemia (AML) in the United States is 68 years. With increasing age, the response rates to standard chemotherapy decrease and early mortality increases. Data from 5 SWOG trials show that the complete response (CR) rates to chemotherapy-based treatment regimens fall from 65% for patients,56 years of age to 46%, 39%, and 33% with each addi...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Fred Hutchinson Cancer Research Center, Seattle, WA; Southwest Oncology Group Statistical Center, Seattle, WA; City of Hope Medical Center, Duarte, CA; University of New Mexico, Albuquerque, NM; Vancouver General Hospital, Vancouver, BC, Canada; University of Toronto, Toronto, Ontario, Canada; University of Chicago, Chicago, IL; University of Michigan, Ann Arbor, MI; Loyola University Medical C...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group
To evaluate the incidence and clinical impact of WT1 gene mutations in younger adult patients with cytogenetically normal acute myeloid leukemia (CN-AML), sequencing of the complete coding region was performed in diagnostic samples from 617 patients who were treated on 3 German-Austrian AML Study Group protocols. WT1 mutations were identified in 78 (12.6%) of the 617 patients; mutations cluster...
متن کامل